Ionis Pharmaceuticals IONS Increase Decrease In Escrow Deposits

Other financials

Revenue$246.1M+87.0%

Gross profit$243.1M+86.8%

Operating income-$117.4M+20.0%

Net income-$92.5M+37.0%

EPS (diluted)-$0.56+39.8%

Cash & equivalents$173.4M-34.4%

Total debt$691.7M+334%

Total equity$491.4M+3.3%

Total assets$3.4B+22.6%

Operating cash flow-$792.8M-426%

CapEx$21.8M+73.0%

Free cash flow-$814.6M-399%

Market cap$12.25B+159%

Enterprise value$12.77B+175%

P/S11.6×+5.0×

Gross margin98.4%-0.2pp

Operating margin-33.3%-11.0pp

Net margin-30.9%-10.5pp

FCF margin-77.4%+35.3pp

Return on equity-67.6%-20.3pp

Debt / equity1.4×+1.1×

Current ratio4.1×-5.6×

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept ions:IncreaseDecreaseInEscrowDeposits.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Ionis Pharmaceuticals's increase decrease in escrow deposits?: Ionis Pharmaceuticals (IONS) reported increase decrease in escrow deposits of $632.51M in Q1 2026.